Definium Therapeutics, Inc. DFTX R2K
Healthcare · Biotechnology · United States
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
READ MORE ›$24.19
+233.20% 1Y
Market & Price
Market Cap
$2.64B
Current Price
$24.19
High / Low (52W)
$24.19 / $6.49
Beta
2.38
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$3.36
Price to Book
7.19
P/S
-
EV/EBITDA
-
Dividend Yield
-
Profitability & Returns
ROCE
-47.75%
ROE
-94.70%
ROA
-35.72%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.71
EPS (TTM)
$-2.50
Balance Sheet & Liquidity
Debt/Equity
0.15
Quick Ratio
4.60
Current Ratio
4.69
Debt
$40.77M
Total Assets
$440.10M
Current Assets
$419.32M
Working Capital
$352.62M
Ownership
Promoter Holding
0.95%
Chg in Prom Hold
-
FII / Inst Holding
74.48%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$2.31B
Total Revenue (TTM)
-
EBITDA
-
Free Cash Flow
$-45.63M
Operating Cash Flow
$-144.77M
Shares Outstanding
109.07M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-74.53%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -74.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DFTX Definium Therapeutics, Inc. R2K | 24.19 | - | $2.64B | - | -47.75% | -94.70% | - | -74.53% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.16M | 40.90M | 45.67M | 47.58M | 59.22M |
| Operating Income | -13.85M | -45.22M | -17.23M | -18.50M | -16.94M | -16.98M | -20.86M | -29.18M | -21.62M | -22.20M | -24.46M | - | - | -32.16M | -40.90M | -45.67M | -47.58M | -59.22M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.75M | -40.41M | -65.99M | -49.17M | -75.85M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 602.00K | 2.34M | 1.27M | 1.27M | 1.25M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -23.35M | -42.74M | -67.27M | -50.44M | -77.10M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -13.76M | -45.25M | -17.20M | -18.45M | -16.96M | -16.48M | -24.82M | -29.13M | -17.92M | -54.40M | -5.85M | - | - | -23.35M | -42.74M | -67.27M | -50.44M | -77.10M |
| Diluted EPS | - | -0.11 | -0.61 | -0.66 | -0.60 | -0.56 | -0.65 | -0.76 | -0.45 | -1.14 | -0.26 | - | -0.41 | -0.35 | -0.50 | -0.78 | - | -0.71 |
| R&D Expense | 6.81M | 8.07M | 9.02M | 10.24M | 9.33M | 7.77M | 12.60M | 14.78M | 13.20M | 11.71M | 14.64M | 17.19M | - | 23.36M | 29.81M | 30.98M | - | 41.48M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 66.33M | 93.87M | 103.92M | 166.31M |
| Operating Income | -33.03M | - | -66.33M | -93.87M | -103.92M | -166.31M |
| EBITDA | - | - | -63.15M | -91.65M | -105.87M | -178.31M |
| Interest Expense | - | 359.00K | - | 920.00K | 2.28M | 5.48M |
| Pretax Income | - | - | -56.80M | -95.73M | -108.68M | -183.79M |
| Tax Provision | - | -1.16M | 0 | - | - | - |
| Net Income | -33.94M | - | -56.80M | -95.73M | -108.68M | -183.79M |
| Diluted EPS | - | -3.45 | -1.84 | -2.44 | -1.54 | - |
| R&D Expense | 18.63M | 34.79M | 36.17M | 52.12M | 65.30M | 117.67M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -74.53% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +233.20% |
| 6 Months: | +103.62% |
| 3 Months: | +38.62% |
| 1 Month: | +18.06% |
Balance Sheet (Annual)
Figures in USD.
| Metric | May 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 81.52M | - | 169.99M | 124.54M | 302.15M | 440.10M |
| Current Assets | - | - | - | - | 146.06M | 103.87M | 281.62M | 419.32M |
| Cash & Equivalents | - | - | 80.09M | - | 142.14M | 99.70M | 273.74M | 257.84M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 5.65M | - | 19.08M | 46.41M | 60.70M | 107.77M |
| Current Liabilities | - | - | 3.01M | - | 17.89M | 32.25M | 38.85M | 66.70M |
| Long Term Debt | - | - | - | - | - | 14.13M | 21.85M | 40.58M |
| Total Debt | - | - | - | - | 72.00K | 14.13M | 21.85M | 40.58M |
| Total Equity | 0 | 4.78M | 75.87M | - | 150.92M | 78.13M | 241.45M | 332.33M |
| Shares Outstanding | - | - | - | - | 37.98M | 41.10M | 75.10M | 98.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.60M | - | -50.14M | -64.36M | -79.13M | -131.56M |
| Investing Cash Flow | - | -297.00K | 0 | - | 0 | -151.61M |
| Financing Cash Flow | 96.70M | - | 59.05M | 21.85M | 253.20M | 267.27M |
| Capital Expenditure | - | - | - | - | - | - |
| Free Cash Flow | - | - | -50.14M | -64.36M | -79.13M | -131.56M |
| Net Change in Cash | - | - | 8.91M | -42.52M | 174.07M | -15.90M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | -44.7% | - | -37.6% | -122.5% | -45.0% | -55.3% |
| ROCE % | -42.1% | - | -43.6% | -101.7% | -39.5% | -44.5% |
Shareholding Pattern
Insiders
0.95%
Institutions
74.48%
Public Float
75.19%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.78% | 8.48M | $205.14M |
| 2 | Driehaus Capital Management, LLC | 5.42% | 5.91M | $143.01M |
| 3 | Avoro Capital Advisors LLC | 4.58% | 5.00M | $120.95M |
| 4 | Janus Henderson Group PLC | 3.26% | 3.56M | $86.02M |
| 5 | Deep Track Capital, Lp | 2.75% | 3.00M | $72.57M |
| 6 | Geode Capital Management, LLC | 2.29% | 2.50M | $60.36M |
| 7 | State Street Corporation | 2.27% | 2.47M | $59.79M |
| 8 | Octagon Capital Advisors LP | 2.24% | 2.44M | $59.02M |
| 9 | Commodore Capital Lp | 1.83% | 2.00M | $48.38M |
| 10 | FMR, LLC | 1.66% | 1.81M | $43.77M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DFTX
No recent headlines available.